ATE386514T1 - Inhibition der vaskulären restenose nach einer angioplastie - Google Patents

Inhibition der vaskulären restenose nach einer angioplastie

Info

Publication number
ATE386514T1
ATE386514T1 AT00913083T AT00913083T ATE386514T1 AT E386514 T1 ATE386514 T1 AT E386514T1 AT 00913083 T AT00913083 T AT 00913083T AT 00913083 T AT00913083 T AT 00913083T AT E386514 T1 ATE386514 T1 AT E386514T1
Authority
AT
Austria
Prior art keywords
angioplasty
vascular restenosis
suppressing
inhibition
inducible
Prior art date
Application number
AT00913083T
Other languages
English (en)
Inventor
Tsuneyuki Nagae
Katsuo Aizawa
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Application granted granted Critical
Publication of ATE386514T1 publication Critical patent/ATE386514T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Laser Surgery Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00913083T 1999-04-02 2000-04-03 Inhibition der vaskulären restenose nach einer angioplastie ATE386514T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9565499 1999-04-02

Publications (1)

Publication Number Publication Date
ATE386514T1 true ATE386514T1 (de) 2008-03-15

Family

ID=14143497

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00913083T ATE386514T1 (de) 1999-04-02 2000-04-03 Inhibition der vaskulären restenose nach einer angioplastie

Country Status (5)

Country Link
EP (1) EP1166784B1 (de)
AT (1) ATE386514T1 (de)
DE (1) DE60038105T2 (de)
ES (1) ES2301480T3 (de)
WO (1) WO2000059505A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060282132A1 (en) * 2003-06-20 2006-12-14 Keio University Photodynamic therapy equipment, method for controlling photodynamic therapy equipment and method of photodynamic method
JP2007091673A (ja) * 2005-09-29 2007-04-12 Toshiba Corp 血液循環促進剤、血液循環装置および血液循環促進医療システム

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3154742B2 (ja) * 1991-04-30 2001-04-09 日本石油化学株式会社 哺乳類の動脈硬化症治療剤
US5422362A (en) * 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
ATE255583T1 (de) * 1998-07-10 2003-12-15 Meiji Seika Kaisha Metallkomplexe von chlorinderivaten zum abschirmen von röntgenstrahlen

Also Published As

Publication number Publication date
EP1166784A1 (de) 2002-01-02
ES2301480T3 (es) 2008-07-01
EP1166784B1 (de) 2008-02-20
DE60038105D1 (de) 2008-04-03
WO2000059505A1 (en) 2000-10-12
DE60038105T2 (de) 2009-03-05
EP1166784A4 (de) 2002-07-24

Similar Documents

Publication Publication Date Title
EP1649853A3 (de) Mikrotubulstabilisatoren zur Behandlung von Artherosklerose oder Restenose
ATE556705T1 (de) Darreichungsform enthaltend taxol in kristalliner form
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
EP1213285A3 (de) 4,5-Diphenyloxazolderivate und ihre Verendung als Blutplättchenaggregations-Inhibitoren
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
WO2004018472A3 (en) Pyrimido compounds having antiproliferative activity
DK0786991T3 (da) Polyaminforbindelsre til behandling af proliferative karsygdomme
DE69223736D1 (de) Acridine-1,8-Dionderivate als therapeutisches Mittel
AR002761A1 (es) Un compuesto derivado del triazol, su uso, una composicion farmaceutica que lo contiene, un metodo de tratamiento o prevencion de una infeccion fungica enun paciente humano mediante dicho compuesto o composicion, y procedimiento y compuestos intermedios para prepararlo.
EP1171145A4 (de) Verwendung von katechin zur prävention oder behandlung koronarer restenosis
WO2000043392A3 (de) Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel
NO164904C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive griseolsyrederivater.
DK0537278T3 (da) PTCA-kateter med en eventuelt fastgjort kernewire
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
DE60038105D1 (de) Inhibition der vaskulären restenose nach einer angioplastie
WO1995015161A3 (de) Arzneimittel zur behandlung der herzinsuffizienz
WO2002087472A8 (en) Stent-based delivery of statins to prevent restenosis
ATE192040T1 (de) Wirkstoff gegen arteriosklerose
GT200100220A (es) Nuevos heteroaromatos.
EP0266559A3 (en) Therapeutic agent for the treatment of peptic ulcer disease
EP1459763A4 (de) Arzneimittel zur verhinderung von gefässrestenose und instrument zur einbettung in ein mit dem arzneimittel überzogenes gefäss
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
NZ527216A (en) Regulation of organic nitrate tolerance
ATE479695T1 (de) Sulfopyranosylacylglycerol-derivate zur anwendung in kombination mit bestrahlung in einer tumor- radiotherapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties